Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

CVFs in SIH: EID vs. PCD CTM

11 de junio de 2026 actualizado por: Duke University

CSF-Venous Fistula Detection in Spontaneous Intracranial Hypotension: Comparative Diagnostic Yields of Energy Integrating Detector Versus Photon Counting Detector CT Myelography

The purpose of this research study is to compare two types of Computed Tomography Myelography (CTM) scans, one on the photon counting detector scanner (called PCD-CTM) and the other on the energy integrating detector scanner (called EID-CTM); both of which doctors usually use to diagnose abnormal connections between the cerebrospinal fluid and the venous system, or CSF-venous fistulas. This study will help to see if the newer PCD-CTM scan can find more spinal fluid leaks [CSF-venous fistulas (CVF)] than the scan that is normally used (EID-CTM).

Descripción general del estudio

Descripción detallada

Spontaneous intracranial hypotension (SIH) is a debilitating condition caused by a spinal CSF leak. One subtype of spinal CSF leak, the CSF-venous fistula (CVF), is a pathologic connection between the CSF-containing nerve root sleeve and an adjacent paraspinal vein. Identifying and localizing the CVF that causes SIH is a critical prerequisite to curative treatment. Visualizing CVFs requires high-quality myelography. Despite improvements in myelographic techniques, CVF identification remains challenging because they are diminutive structures and depend on identifying small volumes of contrast in a paraspinal vein, the "hyperdense paraspinal vein sign."

Compared with EID CT myelography (EID-CTM), PCD-CTM enables much higher spatial resolution and a greater contrast-to-noise ratio, carrying with it the promise of improved detection rates for CVF. Previous publications report early encouraging findings on the benefits of PCD-CTM for CVF detection; however, all prior work has been based on retrospective data. Importantly, these retrospective studies have been biased toward reduced PCD-CTM CVF detection, since only the patients with CVFs that are not definitely identified on EID-CTM undergo PCD-CTM (thus, more challenging cases are completed on the PCD CT). No studies have prospectively demonstrated the additional benefit of PCD-CTM over EID-CTM. Furthermore, no studies have prospectively reported the yield of any type of myelography for CVF detection. Based on the study team's knowledge of these imaging modalities and the imaging appearance of CVFs, PCD-CTM may have a benefit in detecting CVFs that can be missed on EID-CTM, which has been suggested in retrospective studies.

This is a prospective randomized clinical trial designed to assess the diagnostic yield of two different CT scanner types for detecting CSF-venous fistulas (CVFs) during CT myelography. The primary study aim is to compare PCD-CTM to traditional EID-CTM, which is currently the most commonly used technique for CVF detection. Patients meeting inclusion/exclusion criteria will be identified at the Duke CSF Leak Clinic. After informed consent, enrolled participants will be randomized (1:1 allocation) to either PCD-CTM or EID-CTM. CTM technique for both arms will be performed in a standardized manner as part of routine standard of care, as previously published. There will be no additional imaging outside of the current standard of care.

The only intervention in this study is randomization into either of the two imaging arms.

CTM images will be reviewed by the radiologist performing the procedure as part of routine standard of care as well as one additional neuroradiologist. The presence or absence of a CVF will be classified according to the Duke CVF Confidence Score (DCCS). Disagreements will be adjudicated by a third neuroradiologist.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

200

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Primary Clinical Research Coordinator
  • Número de teléfono: 919-684-7810
  • Correo electrónico: latonia.strader@duke.edu

Copia de seguridad de contactos de estudio

  • Nombre: Clinical Research Specialist
  • Número de teléfono: 919-684-3296
  • Correo electrónico: amy.cuddington@duke.edu

Ubicaciones de estudio

    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Reclutamiento
        • Duke University Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Adult patient,
  2. Confirmed diagnosis of SIH using International Classification of Headache Disorders criteria (third edition), and
  3. Brain MRI demonstrating at least one positive imaging finding for SIH (e.g., dural enhancement, venous sinus distention, brain sagging, pituitary engorgement, spontaneous subdural fluid collections).

Exclusion Criteria:

  1. Prior treatment of a CVF,
  2. Inability to undergo both exams (EID-CTM and PCD-CTM) if needed for diagnosis,
  3. Spine MRI demonstrating extradural CSF (confirming CSF leak type other than CVF), and
  4. inability to provide informed consent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Photon counting detector CT myelography (PCD-CTM)
Randomization (1:1) to either photon counting detector CT myelography (PCD- CTM) or energy integrating detector CT myelography (EID-CTM)
Otro: Energy integrating detector CT myelography (EID-CTM)
Randomization (1:1) to either photon counting detector CT myelography (PCD- CTM) or energy integrating detector CT myelography (EID-CTM)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diagnostic Yield of CTM for CVF Detection Using DCCS
Periodo de tiempo: Initial interpretation by radiologist performing procedure: within 4 weeks of completion of CTM. Secondary interpretation by additional neuroradiologist and adjudication by third (when needed): completion of study (approximately 3 years)
Diagnostic yield will be calculated in both arms as the fraction of patients in whom at least one definite CVF (DCCS 3) is identified. CTM images from both arms will be reviewed by the radiologist performing the procedure as part of routine standard of care, as well as one additional neuroradiologist. The presence or absence of a CVF will be classified according to the Duke CVF Confidence Score (DCCS). Disagreements will be adjudicated by a third neuroradiologist.
Initial interpretation by radiologist performing procedure: within 4 weeks of completion of CTM. Secondary interpretation by additional neuroradiologist and adjudication by third (when needed): completion of study (approximately 3 years)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Timothy J Amrhein, MD, Duke University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

21 de mayo de 2026

Finalización primaria (Estimado)

1 de junio de 2028

Finalización del estudio (Estimado)

1 de agosto de 2028

Fechas de registro del estudio

Enviado por primera vez

6 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

6 de mayo de 2026

Publicado por primera vez (Actual)

13 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

15 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de junio de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir